| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/24/2005 | US20050043704 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 02/24/2005 | US20050043409 Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/24/2005 | US20050043407 Opioid receptor antagonist and cannabinoid receptor antagonist for treatment of alcohol, cocaine, and/or tobacco dependence |
| 02/24/2005 | US20050043406 Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 02/24/2005 | US20050043399 Dimeric compounds and their use as anti-viral agents |
| 02/24/2005 | US20050043398 such as 2-ethoxycarbonyl-7-hydroxychromone, for the care, preservation or improvement of the general state of the skin or hair |
| 02/24/2005 | US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate |
| 02/24/2005 | US20050043393 Antilipemic agents |
| 02/24/2005 | US20050043391 Cicletanime and calcium antagonist and, or ace inhibitors |
| 02/24/2005 | US20050043386 2-amino-2-(ethyl or methyl)-4-{5-substituted pyrrol-2-yl}butan-1-ols, phosphates and phosphonates; antiarthritic agents; psoriasis; immunosuppressants |
| 02/24/2005 | US20050043383 Combined agents for treatment of glaucoma |
| 02/24/2005 | US20050043382 Novel combination of a factor Xa inhibitor and clopidogrel |
| 02/24/2005 | US20050043380 Composition for treatment of malignant tumors |
| 02/24/2005 | US20050043376 Epothilone A and B; desoxyepothilone A and B; anticancer agenst |
| 02/24/2005 | US20050043362 Use of compounds |
| 02/24/2005 | US20050043355 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| 02/24/2005 | US20050043349 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 02/24/2005 | US20050043346 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043345 Opioid receptor antagonist and cannabinoid receptor antagonist for treatment of alcohol, cocaine, and/or tobacco dependence |
| 02/24/2005 | US20050043343 Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
| 02/24/2005 | US20050043327 Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 02/24/2005 | US20050043323 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/24/2005 | US20050043293 Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 02/24/2005 | US20050043284 containing an anti-inflammatory and anti-allergic compound of the androstane series |
| 02/24/2005 | US20050043269 Pharmaceutically active uridine esters |
| 02/24/2005 | US20050043256 antisense oligonucleotides, are targeted to a nucleic acid encoding stearoyl-CoA desaturase, and modulate the expression of stearoyl-CoA desaturase; gene therapy; genetic engineering; for treatment of abnormal lipid metabolism, obesity |
| 02/24/2005 | US20050043242 Using dietary restriction to lower serum insulin levels and function along with troglitazone in treatment and prevention of alzheimer's diseases |
| 02/24/2005 | US20050043238 Exendin formulations for weight reduction |
| 02/24/2005 | US20050043233 Comprising an antagonist of at least one receptor selected from VEGFR 1 to 3, PDGFR alpha and beta , FGFR1, 2 and 3, EGFR, HER2, IGF1R, HGFR or c-Kit, which is further an antagonist of a src tyrosine kinase family member, and a chemotherapeutic agent; co-treatment with radiation therapy |
| 02/24/2005 | US20050043224 Administering to patient a pharmaceutical preparation comprising at least one chemoprotective inducing agent and a vehicle for delivering chemoprotective inducing agent to cells lining hair follicles, in an amount and for a time effective to reduce or prevent hair loss |
| 02/24/2005 | US20050043222 Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application |
| 02/24/2005 | US20050043212 Drug design of a preferential enzyme inhibitor of the p38 Mitogen-activated protein kinase alpha isoform |
| 02/24/2005 | US20050042738 Carbohydrate-associated proteins |
| 02/24/2005 | US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders |
| 02/24/2005 | US20050042724 Sodium-dependent phosphate cotransporter (NAPTR) for use tool in identifying modulators for treatment and prevention of cell proliferative, nervous system and cardiovascular disorders |
| 02/24/2005 | US20050042690 Diagnosis and management of infection caused by chlamydia |
| 02/24/2005 | US20050042671 Modulation of angiogenesis |
| 02/24/2005 | US20050042655 Using hematopoietoic regulatory related polypeptide (HEMA) for use in diagnosis, treatment and prevention of hematopoietic disorders |
| 02/24/2005 | US20050042653 Human transport protein homologs |
| 02/24/2005 | US20050042317 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 02/24/2005 | US20050042312 Solubility and Absorption Promoter |
| 02/24/2005 | US20050042304 Novel substituted benzimidazole dosage forms and method of using same |
| 02/24/2005 | US20050042303 Therapeutic protocols |
| 02/24/2005 | US20050042295 Anti-angiogenic compositions and methods of use |
| 02/24/2005 | US20050042272 Vesiles derived from t cells, production and uses |
| 02/24/2005 | US20050042271 Analgesics; antiinflammatory agents; sustained release |
| 02/24/2005 | US20050042249 Warming and nonirritating lubricant compositions and method of comparing irritation |
| 02/24/2005 | US20050042248 Mixture of polyol and insulation agent; gelation; dysmenorrhea |
| 02/24/2005 | US20050042236 Plant extract active as an immunostimulating agent |
| 02/24/2005 | US20050042215 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 02/24/2005 | US20050042210 Body tissue filling material, production method thereof and body tissue filler |
| 02/24/2005 | US20050042209 Enhancing the induction apoptosis in a MUC1 expressing cancer cell by a pro-apoptotic drugs; antiproliferative agents |
| 02/24/2005 | US20050042207 Escherichia bacteria; diarrhea, autoimmune diseases, microbial infections, irritable bowel syndrome, and inflammatory bowel disease; side effect reduction |
| 02/24/2005 | US20050042202 Gentamicin, amikacin, tobramycin, netilmicin, cephalosporin, ceftazidine, maxalactam, carbopenem, imipenem, aztreonam, ampicillin, penicillin, ureidopenicillin, augmentin, amphotericin, famvir and/or acyclovir; and Vpr protein, fragment or nucleic acid encoding; systemic inflammatory response syndrome |
| 02/24/2005 | US20050042201 Synergistic mixture of glycoprotein and angiogenesis inhibitor comprising angiostatin, thrombostatin, endostatin, interferon, interferon-inducible factor 10, platelet factor, and/or cyclooxygenase inhibitor; antitumor and anticarcinogenic agents |
| 02/24/2005 | US20050042188 A 4-hydroxy-L-proline alkyl ester; sunscreen agents |
| 02/24/2005 | US20050042186 Synergistic oil in water emulsions of biomelanin extract, green tea polyphenols and inorganic pigments; improved cytoprotectivity from free radicals; waterproofing |
| 02/24/2005 | US20050042175 Combined doses of formoterol and budesonide |
| 02/24/2005 | US20050042174 Consistent inhalation dry powder metered doses; concurrent delivery of bronchodilator, anticholinergic agent and antiinflammatory steroid |
| 02/24/2005 | US20050042171 Only once daily administration of an antispasmodic beta-2 adrenergic agonist and an antiinflammatory corticosteroid; inhalation; salmeterol xinafoate |
| 02/24/2005 | DE10333240A1 Therapy for traumatic injuries or coronary conditions involves use of immunosuppressives or ethyl alcohol infusions, each in addition to conventional therapies |
| 02/24/2005 | CA2535892A1 A stable liquid probiotic composition, preparation and applications thereof |
| 02/24/2005 | CA2535670A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
| 02/24/2005 | CA2535451A1 Method of treating viral infections |
| 02/24/2005 | CA2534922A1 Composition comprising a zeolite compound for treatment of diseases |
| 02/24/2005 | CA2534197A1 Use of a vegf antagonist in combination with radiation therapy |
| 02/24/2005 | CA2533730A1 Methods for treatment of dermatological conditions |
| 02/24/2005 | CA2516425A1 Rna interference compositions and methods |
| 02/24/2005 | CA2497198A1 Agents and methods for treatment of disease by oligosaccharide targeting agents |
| 02/23/2005 | EP1508619A1 Novel promoter |
| 02/23/2005 | EP1508331A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection |
| 02/23/2005 | EP1508327A1 Use of chromen-4-one derivatives for the care of skin and hair |
| 02/23/2005 | EP1507875A2 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/23/2005 | EP1507813A1 Fat binding using inter-polymer complex of glucosamine and polyacrylic acid |
| 02/23/2005 | EP1507800A1 Use of monocarboxylate transporter protein for thyroid hormone transport |
| 02/23/2005 | EP1507765A2 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 02/23/2005 | EP1507760A1 Cyanoguanidine prodrugs |
| 02/23/2005 | EP1507759A1 Cyanoguanidine produgs |
| 02/23/2005 | EP1507558A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 02/23/2005 | EP1507556A2 Calicheamicin derivative-carrier conjugates |
| 02/23/2005 | EP1507555A2 Induction of antigen specific immunologic tolerance |
| 02/23/2005 | EP1507554A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2005 | EP1507553A2 Pancreas-specific proteins |
| 02/23/2005 | EP1507551A2 The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells |
| 02/23/2005 | EP1507546A2 Methods of using 22417, a novel human aminoprotease family member |
| 02/23/2005 | EP1507544A1 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/23/2005 | EP1507537A1 Combination of an ace inhibitor, a calcium channel blocker and a diuretic |
| 02/23/2005 | EP1507536A2 Compositions and their uses for alleviating pain |
| 02/23/2005 | EP1507529A1 Combination of organic compounds |
| 02/23/2005 | EP1507528A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 02/23/2005 | EP1507527A2 Methods for enhancing motor performance and/or endurance |
| 02/23/2005 | EP1507525A1 Non-steroidal anti-androgen therapy |
| 02/23/2005 | EP1507516A1 Co-grinding process for the preparation of a ternary composition |
| 02/23/2005 | EP1507504A1 Cycloalkyl inhibitors of potassium channel function |
| 02/23/2005 | EP1175224B1 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy |
| 02/23/2005 | EP1119350B1 Rar antagonists as male anti-fertility agents |
| 02/23/2005 | CN1585900A Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin |
| 02/23/2005 | CN1585771A Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 02/23/2005 | CN1585770A Reverse-turn mimetics and method relating thereto |
| 02/23/2005 | CN1585768A Pyrazole derivatives as psychopharmaceuticals |